Seegene Awarded Patent for Haplotyping Using Multiplex PCR
Haplotyping genetic screening technique promises to accelerate detection of unique personal traits for disease risk and drug response
The patent (WO/2008/143367) issued by the World Intellectual Property Organization covers a novel method for ApoE haplotyping using multiplex PCR. Seegene's proprietary Dual Priming Oligonucleotide (DPO(TM)) technology is being applied to haplotyping - the investigation of the genetic background and phenotype structures of complex diseases.
According to Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene, "This novel approach to haplotyping using the Seegene multiplex platform allows biomedical researchers to cross a barrier that to this point has frustrated many - the exploration of observed patterns of genetic sequences that help us understand how the diverse traits reveal themselves as true risks for individuals."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.